IQVIA (IQV) Stock Outlook 2026: The Company That Owns Both the Data and the Trial
IQVIA (IQV) stock analysis for 2026 covering the Technology & Analytics Solutions (TAS) data business, the R&DS clinical CRO segment, competition from ICON, Labcorp/Fortrea and Thermo Fisher PPD, biotech funding sensitivity, AI in clinical trials, RFP and backlog dynamics, and key risks.
IQV IQVIA CRO